Chembio Names Michael Steele Vice President Of Sales, Marketing & Business Development

MEDFORD, N.Y., Aug. 21, 2012 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, announces the appointment of Michael Steele as Vice President of Sales, Marketing & Business Development, a newly created position. Mr. Steele brings to Chembio a 20-year record of driving growth in general management, corporate business development, strategic account sales, alliance management, and strategy formulation and execution at life sciences companies.

Since April 2012 Mr. Steele has been engaged by Chembio as Corporate Business Development Consultant. From 2008 to 2011 he was Vice President, Business Development of Seracare Life Sciences, Inc., a global provider of products and services to in-vitro diagnostic and biopharmaceutical manufacturers. In that role, he was responsible for strategic plan formulation, corporate business development and strategy projects. Prior to that he was Director and Managing Director at Serologicals Corporation (acquired by Millipore, Inc.), where he had business development, general management and operational responsibilities. Mr. Steele has also held senior business development roles at smaller biotechnology companies, including Corautus Genetics Inc. and Life Therapeutics Ltd. Mr. Steele received a Master of Business Administration and a Bachelor of Science from James Madison University.

Commenting on his appointment, Mr. Steele said, "With a rich portfolio of technologies that deliver enhanced performance and multiplexing capabilities, Chembio is well positioned to fulfill its mission of providing high-quality, cost-effective point-of-care clinical diagnostic products. I am pleased to be joining the Company at such an exciting time."

Lawrence Siebert, Chembio's CEO, commented, "We are delighted to have Mike join our management team and to help drive Chembio's commercial opportunities.  It has been a pleasure working with Mike these last several months during which he has helped to assess and move forward existing projects and identify several new ones.  Consequently, I am confident that he can and will contribute significantly to our growth and success."  

If you liked this article you might like

3 Drugs Stocks Pushing Industry Growth

3 Stocks Advancing The Drugs Industry

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Advancing The Drugs Industry